CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Lifestyle Modifications for Preventing and Treating Heart Failure Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure

Expert Opinionhttps://academic.oup.com/eurheartj/article-abstract/41/39/3784/5686010?redirectedFrom=fulltext

JOURNAL:Eur Heart J. Article Link

Dilated cardiomyopathy: so many cardiomyopathies!

G Sinagra, PM Elliott, M Merlo et al. Keywords: DCM; LV; HF

ABSTRACT

The current definition of dilated cardiomyopathy (DCM) is relatively simple; namely, a heart muscle disease characterized by left ventricular (LV) or biventricular dilation and systolic dysfunction in the absence of either pressure or volume overload or coronary artery disease sufficient to explain the dysfunction.1 In the last decades, the prognosis of patients with DCM has improved significantly with survival free from death and heart transplantation rising to more than 80% at 8-year follow-up.2 This improvement in outcomes reflects the implementation of pharmacological and non-pharmacological therapeutic strategies, earlier diagnosis due to familial and sport-related screening, and individualized long-term follow-up with continuous restratification of risk.